54
Views
6
CrossRef citations to date
0
Altmetric
Original Research

Effects of combined dietary supplementation with fenofibrate and Schisandrae Fructus pulp on lipid and glucose levels and liver function in normal and hypercholesterolemic mice

, , , , , , , & show all
Pages 923-935 | Published online: 17 Feb 2015

References

  • LiWWangDSongGZuoCQiaoXQinSThe effect of combination therapy of allicin and fenofibrate on high fat diet-induced vascular endothelium dysfunction and liver damage in ratsLipids Health Dis2010913121073749
  • ParikhNHParikhPKKothariCIndigenous plant medicines for health care: treatment of diabetes mellitus and hyperlipidemiaChin J Nat Med201412533534424856756
  • BauerUEBrissPAGoodmanRABowmanBAPrevention of chronic disease in the 21st century: elimination of the leading preventable causes of premature death and disability in the USALancet20143849937455224996589
  • PanSYGaoSHZhouSFTangMKYuZLKoKMNew perspectives on complementary and alternative medicine: an overview and alternative therapyAltern Ther Health Med2012184203622875591
  • KeatingGMCroomKFFenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitusDrugs200767112115317209672
  • IkewakiKTohyamaJNakataYWakikawaTKidoTMochizukiSFenofibrate effectively reduces remnants, and small dense LDL, and increases HDL particle number in hypertriglyceridemic men – a nuclear magnetic resonance studyJ Atheroscler Thromb200411527828515557710
  • OhtaTMasutomiNTsutsuiNUntargeted metabolomics profiling as an evaluative tool of fenofibrate-induced toxicology in Fischer 344 male ratsToxicol Pathol200937452153519458390
  • HajduDAiglováKVinklerováIUrbánekKAcute cholestatic hepatitis induced by fenofibrateJ Clin Pharm Ther200934559960219744016
  • DohmenKWenCYNagaokaSFenofibrate-induced liver injuryWorld J Gastroenterol200511487702770316437706
  • PanossianAWikmanGPharmacology of Schisandra chinensis Bail.: an overview of Russian research and uses in medicineJ Ethnopharmacol2008118218321218515024
  • XiongJGuoYLiLYA herbal composition of semen hoveniae, radix puerariae, and Fructus Schisandrae shows potent protective effects on acute alcoholic intoxication in rodent modelsEvid Based Complement Alternat Med2012201263819723118795
  • XieWDuLDiabetes is an inflammatory disease: evidence from traditional Chinese medicinesDiabetes Obes Metab201113428930121205111
  • JeongSIKimSJKwonTHYuKYKimSYSchizandrin prevents damage of murine mesangial cells via blocking NADPH oxidase-induced ROS signaling in high glucoseFood Chem Toxicol2012503–41045105322138248
  • KwonDYKim daSYangHJParkSThe lignan-rich fractions of Fructus Schisandrae improve insulin sensitivity via the PPAR-γ pathways in in vitro and in vivo studiesJ Ethnopharmacol2011135245546221440615
  • PanSYYuQZhangYDietary Fructus Schisandrae extracts and fenofibrate regulate the serum/hepatic lipid-profile in normal and hypercholesterolemic mice, with attention to hepatotoxicityLipids Health Dis20121112022989092
  • SunNPanSYZhangYDietary pulp from Fructus Schisandra chinensis supplementation reduces serum/hepatic lipid and hepatic glucose levels in mice fed a normal or high cholesterol/bile salt dietLipids Health Dis2014134624621253
  • WangXYYuZLPanSYSupplementation with the extracts of Schisandrae Fructus pulp, seed, or their combination influences the metabolism of lipids and glucose in mice fed with normal and hypercholesterolemic dietEvid Based Complement Alternat Med2014201447263824876871
  • PanSYDongHZhaoXYSchisandrin B from Schisandra chinensis reduces hepatic lipid contents in hypercholesterolaemic miceJ Pharm Pharmacol200860339940318284822
  • PanSYYangRDongHYuZLKoKMBifendate treatment attenuates hepatic steatosis in cholesterol/bile salt- and high-fat diet-induced hypercholesterolemia in miceEur J Pharmacol20065521–317017517046746
  • PanSYDongHYuZLBicyclol, a synthetic dibenzocyclooctadiene derivative, decreases hepatic lipids but increases serum triglyceride level in normal and hypercholesterolaemic miceJ Pharm Pharmacol200759121657166218053327
  • HuWLIYZhangCZEnantioseparation of racemic anti-hepatitis new drug bicyclol with crystallizationChin Chem Lett2005161114711473
  • LiXZhouJChenSRole of bicyclol in preventing chemotherapeutic agent-induced liver injury in patients over 60 years of age with cancerJ Int Med Res201442490699124903556
  • LiuGTBicyclol: a novel drug for treating chronic viral hepatitis B and CMed Chem200951294319149648
  • KumarDSPrashanthiGAvasaralaHBanjiDAntihypercholesterolemic effect of Macrotyloma uniflorum (Lam.) Verdc (Fabaceae) extract on high-fat diet-induced hypercholesterolemia in Sprague-Dawley ratsJ Diet Suppl201310211612823725525
  • LinZJZhangBLiuXQYangHLAbdominal fat accumulation with hyperuricemia and hypercholesterolemia quail model induced by high fat dietChin Med Sci J200924319119419848323
  • SharrettARBallantyneCMCoadySAAtherosclerosis Risk in Communities Study GroupCoronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein (a), apolipoproteins A-I and B, and HDL density subfraction: the atherosclerosis risk in communities (ARIC) studyCirculation2001104101108111311535564
  • BarterPGottoAMLaRosaJCTreating to New Targets InvestigatorsHDL cholesterol, very low levels of LDL cholesterol, and cardiovascular eventsN Engl J Med2007357131301131017898099
  • HsiaSHPanDBerookimPLeeMLA population-based, cross-sectional comparison of lipid-related indexes for symptoms of atherosclerotic diseaseAm J Cardiol20069881047105217027569
  • AndersonTJGrégoireJHegeleRA2012 update of the Canadian cardiovascular society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adultCan J Cardiol201329215116723351925
  • DengBOuSQZhengZFThe relationship of LDL-c/HDL-c ratio with coronary artery disease degree and acute coronary syndromesChin J Hypertension2005139541544
  • BaligadooSElevated coronary mortality in Mauritius: risk factors and genetic analysesBull Acad Natl Med201219671381139423815022
  • SchofieldJDLiuYFranceMWSandleLSoranHA review of paradoxical HDL-C responses to fenofibrate, illustrated by a case reportJ Clin Lipidol20148445545925110229
  • LinzPELovatoLCByingtonRPParadoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid TrialDiabetes Care201437368669324296848
  • LellaMIndiraKA comparative study of efficacy of atorvastatin alone and its combination with fenofibrate on lipid profile in type 2 diabetes mellitus patients with hyperlipidemiaJ Adv Pharm Technol Res20134316617024083205
  • NiesorEJGauthamadasaKSilvaRAXanthophylls, phytosterols and pre-β1-HDL are differentially affected by fenofibrate and niacinHDL-raising in a cross-over studyLipids201348121185119624068631
  • EnomotoMAdachiHHiraiYLDL-C/HDL-C ratio predicts carotid intima-media thickness progression better than HDL-C or LDL-C aloneJ Lipids2011201154913721773051
  • TrapaniLSegattoMPallottiniVRegulation and deregulation of cholesterol homeostasis: the liver as a metabolic “power station”World J Hepatol20124618419022761969
  • ChuJHWangHYeYInhibitory effect of schisandrin B on free fatty acid-induced steatosis in L-02 cellsWorld J Gastroenterol201117192379238821633637
  • EspenshadePJHughesALRegulation of sterol synthesis in eukaryotesAnnu Rev Genet20074140142717666007
  • XuXSoJSParkJGLeeAHTranscriptional control of hepatic lipid metabolism by SREBP and ChREBPSemin Liver Dis201333430131124222088
  • GrubenNShiri-SverdlovRKoonenDPHofkerMHNonalcoholic fatty liver disease: a main driver of insulin resistance or a dangerous liaison?Biochim Biophys Acta20141842112329234325128743
  • KellyCTMansoorJDohmGLChapmanWH3rdPenderJR4thPoriesWJHyperinsulinemic syndrome: the metabolic syndrome is broader than you thinkSurgery2014156240541124962189
  • SmithBWAdamsLANon-alcoholic fatty liver diseaseCrit Rev Clin Lab Sci20114839711321875310
  • JeongSYoonMFenofibrate inhibits adipocyte hypertrophy and insulin resistance by activating adipose PPAR alpha in high fat diet-induced obese miceExp Mol Med200941639740519322024
  • KostapanosMSKeiAElisafMSCurrent role of fenofibrate in the prevention and management of non-alcoholic fatty liver diseaseWorld J Hepatol20135947047824073298
  • KwonDYda KimSYangHJParkSThe lignan-rich fractions of Fructus Schisandrae improve insulin sensitivity via the PPAR-γ pathways in in vitro and in vivo studiesJ Ethnopharmacol2011135245546221440615
  • JosephBKapoorSSchilskyMLGuptaSBile salt-induced pro-oxidant liver damage promotes transplanted cell proliferation for correcting Wilson disease in the long-evans cinnamon rat modelHepatology20094951616162419185006
  • CanetMJCherringtonNJDrug disposition alterations in liver disease: extrahepatic effects in cholestasis and nonalcoholic steatohepatitisExpert Opin Drug Metab Toxicol20141091209121924989624
  • KobayashiASuzukiYKunoHSugaiSSakakibaraHShimoiKEffects of fenofibrate on plasma and hepatic transaminase activities and hepatic transaminase gene expression in ratsJ Toxicol Sci200934437738719652460
  • GuoLYHungTMBaeKHAnti-inflammatory effects of schisandrin isolated from the fruit of Schisandra chinensis BaillEur J Pharmacol20085911–329329918625216
  • LouXEXuNYaoHPChenZBicyclol attenuates pro-inflammatory cytokine and chemokine productions in CpG-DNA-stimulated L02hepatocytes by inhibiting p65-NF-kappaB and p38-MAPK activationPharmazie201065320621220383942
  • ZhangYPanSYZhouSFTime- and dose-toxicity relationships of schisandrin B- and Schisandrae Fructus oil-induced hepatotoxicity associated with triglyceride elevation in serum and liver in miceDrug Des Devel Ther2014814291439
  • KonesRPrimary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive surveyDrug Des Devel Ther20115325380